drugset

drugset / Trial / NCT01455584

Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors

NCT01455584 ↗

Phase 1 Completed 20 enrolled Hanmi Pharmaceutical Company Limited

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main objective of this study is to determine the maximum tolerated dose (MTD) of HM781-36B continuously.

Timeline

Start: 2011-06
Primary completion: 2013-05
Completion: 2013-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Poziotinib	Small molecule	—	—

Indications